Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

7(77.8%)

Phase 3

1(11.1%)

Phase 2

1(11.1%)

9Total

Phase 1(7)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06768905Phase 1Recruiting

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

Role: collaborator

NCT07157514Phase 2Not Yet Recruiting

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Role: lead

NCT07015684Phase 1Recruiting

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

Role: collaborator

NCT03867682Phase 1Unknown

Venetoclax and Lintuzumab-Ac225 in AML Patients

Role: lead

NCT03932318Phase 1Withdrawn

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Role: lead

NCT02575963Phase 1Completed

Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

Role: lead

NCT02665065Phase 3Active Not Recruiting

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Role: lead

NCT02998047Phase 1Terminated

A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

Role: lead

NCT00672165Phase 1Completed

Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies

Role: collaborator

All 9 trials loaded